Pharma firm Abbott India has posted a rise of 44.46% in its net profit of Rs 36.88 crore for the fourth quarter ended December. The company had posted net profit of Rs 25.53 in the same quarter in 2010. Net sales of the company during Q4 stood at Rs 383.60 crore, as against Rs 268.53 crore in the same period, up by 42.85%.
Due to change in the accounting system and ongoing scheme of amalgamation, the results of the quarter and the year ended December 31, 2011 are not comparable with those of the corresponding periods of the previous year.
For the year ended December 31, 2011, the company posted a net profit of Rs 120.39 crore. The company had posted a net profit of Rs 60.94 crore in 2010.
The company’s board has recommended a final dividend of Rs 17 per equity share of the face value of Rs 10 each.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1847.30 |
| Dr. Reddys Lab | 1293.25 |
| Cipla | 1347.70 |
| Zydus Lifesciences | 938.90 |
| Lupin | 2377.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: